Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure

Leen Delrue1, Marc Vanderheyden1, Monika Beles1, Pasquale Paolisso1,2, Giuseppe Di Gioia1,2, Riet Dierckx1, Sofie Verstreken1, Marc Goethals1, Ward Heggermont1 and Jozef Bartunek1*

1Cardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium; and 2Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

Abstract

Aims We investigated the prognostic relevance of serpin peptidase inhibitor, clade A member 3 (SERPINA3) in patients admitted with a de novo or worsened heart failure (HF).

Methods and results In the first stage, 83 HF-related left ventricular (LV) transcripts were examined in patients with congestive cardiomyopathy (CCMP, n = 44) who died within 5 years and compared with age-matched and haemodynamically matched CCMP survivors (n = 39) and controls with normal LV function (n = 17). Among 14 differentially expressed transcripts, myocardial gene and circulating SERPINA3 levels were up-regulated in non-survivors vs. survivors (2.40 ± 3.66 vs. 0.36 ± 0.22 units, P < 0.01 and 334.7 ± 138.7 vs. 228.2 ± 83.1 μg/mL, P < 0.01, respectively). While no significant transmyocardial gradient was detected, cytokine stimulation of human endothelial cells induced SERPINA3 secretion. In an independent validation cohort with a de novo or worsened HF (n = 387), circulating SERPINA3 levels > 316 μg/mL were associated with increased all-cause mortality [hazard ratio [HR] [95% confidence interval (CI)]: 2.4 [1.5–3.9], P = 0.0002] and its composite with unplanned cardiovascular readmission [HR (95% CI): 2.0 (1.2–3.3), P = 0.004]. Patients with elevated SERPINA3 levels and elevated either N-terminal pro brain natriuretic peptide or ST2 showed worse freedom from both endpoints. In a multivariate analysis, including established clinical risk factors, SERPINA3 remained independent predictor of all-cause mortality together with age, gender, ST2, glomerular filtration, and pulmonary capillary wedge pressure.

Conclusion In patients with a de novo or worsened HF, increased SERPINA3 levels > 316 μg/mL are associated with increased mortality or unplanned cardiac readmission. Elevated SERPINA3 levels on top of established clinical predictors appear to identify a subgroup of HF patients at higher mortality risk. Prospective studies should further validate its value in prognostic stratification of HF.

Keywords Heart failure; Prognosis; Biomarkers; Inflammation; Cardiomyopathy

Introduction

Heart failure is a complex clinical syndrome, and its prognostic stratification remains challenging. Several biomarkers have been introduced to aid the clinical guidance and prognostic stratification of heart failure patients. Nevertheless, the prognostic value of individual biomarkers falls often short to address the prognostic stratification at individual patient level. This may be related to the complex pathophysiology and heterogeneous nature of heart failure syndrome where a single marker may not yield optimal precision at the patient level. Alternative approach in scoping relevant biomarkers could be based on comparative analyses of molecular fingerprints.
of well-defined cohorts at index clinical and haemodynamic evaluation and known clinical outcomes. Here, we postulated that using the pre-defined panel of transcripts involved in myocardial structural remodelling and function, we may identify most relevant heart failure biomarkers. Using this strategy, we identified differential expression of SERPINA3 in a well-defined cohort of phenotypically matched survivors and non-survivors with congestive cardiomyopathy. SERPINA3, also known as alpha-1 antichymotrypsin, acts as an inhibitor of several serine proteases. Insufficient serpin regulation can cause excessive or prolonged cathepsin G activity, ultimately leading to tissue damage.8 SERPINA3 in heart failure has been suggested by observing a decrease in plasma SERPINA3 levels in end-stage heart failure patients with favourable remodelling under mechanical haemodynamic support.9 Accordingly, we further investigated the potential prognostic value of SERPINA3 and report on its association with poor survival in patients with a de novo or worsened heart failure.

**Methods**

**Patients**

We studied a total of 487 patients in two separate cohorts. First, we selected 100 patients to address the differential myocardial gene expression related to survival in heart failure due to congestive idiopathic cardiomyopathy. They had no history of coronary artery disease or intervention, were free due to congestive idiopathic cardiomyopathy. They had no myocardial gene expression related to survival in heart failure.

We studied a total of 487 patients in two separate cohorts. Methods

**RNA preparation and quantitative RT-PCR**

Total RNA was extracted from the tissues using RNeasy Fibrous Tissue Mini Kit, from blood using QiAamp RNA Blood Mini Kit and from cells using miRNeasy Mini Kit (Qiagen, Venlo, Netherlands) following the manufacturer’s instructions. Reverse transcription was performed with random primers using High-Capacity cDNA Archive System (Applied Biosystems, Foster City, CA). Quantitative RT-PCR was subsequently performed with TaqMan Gene Expression Assays using a 7500 real-time PCR system (Applied Biosystems). Expression data were normalized to the housekeeping gene GAPDH in the same sample and expressed in arbitrary units. We compared gene transcripts of 83 transcripts involved in heart failure progression and implicated in pathophysiology of heart failure (Supporting Information, Table S2).

**Circulating biomarkers and SERPINA3 plasma levels**

Blood samples were centrifuged for 10 min at 4000 rpm within 30 min of collection. Plasma was extracted and stored at ≤–20°C until analysis. Circulating SERPINA3 and ST2 levels were determined using a commercially available ELISA kit (Human Alpha 1-Antichymotrypsin ELISA, Immunology Consultants Laboratory, Inc., USA and Presage ST2 Assay, Critical Diagnostics, CA, USA) according to the manufacturer’s instructions. Serum N-terminal pro brain natriuretic peptide (NT-proBNP) levels were determined with an electrochemiluminescence immunoassay (Elecsys NT-proBNP, Diagnostics Roche). Baseline sST2 value of >35 ng/mL has been accepted by US Food and Drug Administration as a predictor of worse prognosis [http://www.accessdata.fda.gov/ cdrh_docs/reviews/k111452.pdf (Assessed 02 April 2017)] while the reference value for NT-proBNP is set at 100 pg/mL10 to indicate risk of poor clinical outcome. Other biochemical and haematological parameters were measured by standard procedures.

**Cultured cells**

Human coronary artery endothelial cells and human umbilical vein endothelial cells were obtained from Lonza, and blood outgrowth endothelial cells were isolated in our lab from peripheral blood of heart failure patients. Cells were cultured in endothelial medium at passage 3–5. To examine SERPINA3 production in response to inflammatory cytokines, cells were stimulated with interleukin-1β (20 ng/mL) or tumour necrosis factor-α (30 mg/mL) (R&D Systems, Minneapolis, MN). Culture supernatant was assayed for SERPINA3 1, 3, 5, 17, and 24 h after treatment.
Western blotting

Left ventricular myocardial biopsies or cells were lysed in RIPA protein lysis buffer containing PMSF and protease inhibition cocktail (Roche Diagnostics GmbH, Mannheim, Germany) using the Bead Ruptor 4 Mini Homogenizer (Omnifit International). Protein concentration was determined with a BCA protein assay kit (Thermo Scientific, Rockford, USA). Protein extracts were separated on a polyacrylamide gel and subsequently transferred to a PVDF membrane. The membrane was blocked in 5% non-fat dry milk/TBS-T buffer followed by overnight incubation at 4°C with primary antibody. After rinsing, the membrane was incubated with HRP conjugated secondary antibody and detected by use of the ECL detection kit (Bio-Rad). Densitometric quantification of protein bands was performed with the Chemidoc Touch Imaging System (Bio-Rad). Following antibodies were used: anti-SERPINA3 rabbit monoclonal antibody (ab205197, Abcam, Cambridge), Akt antibody (#9272) (Cell Signaling Technologies, Massachusetts), and HRP conjugated goat anti-rabbit IgG secondary antibody (TA1300233, Origene). GAPDH was used to normalize for different protein content using GAPDH antibody (sc-47724) and mlgG κ BP-HRP (sc-516102) (Santa Cruz Biotechnology, Inc, Dallas, Texas).

Data and statistical analysis

Statistical analysis was performed using Software R 3.6.2.11 Data are presented as mean ± SD for continuous variables and as percentages for categorical variables. We compared the median of the three groups with the Kruskal–Wallis test followed by Dunn’s multiple comparison testing for differences in pairs. For two groups, data were analysed using Mann–Whitney t-test. Univariate and multivariate linear regression were used to predict SERPINA3 plasma levels. A log10 transformation was applied to the right skewed outcome variable. Univariate parameter estimates with P < 0.1 significance level was considered further in a multivariate model. In case of high correlation between two possible predictors, two heart failure specialists determined by consensus the parameter to be used for the analysis. Following parameters were included in a univariate model: age, gender, left ventricle ejection fraction, LV end-diastolic dimension, mean pulmonary artery pressure, mean pulmonary capillary wedge pressure, white blood cells count, haemoglobin, estimated glomerular filtration rate (eGFR), NT-proBNP, ST2, and C-reactive protein (CRP) plasma levels. Graphical assessment was used to check the normality assumption of the residuals.

To calculate the cut-off value of log10 SERPINA3 levels for predicting the mortality, the restricted cubic spline curve of log10 SERPINA3 levels were plotted against the predicted hazard ratios (HRs) of the univariate Cox proportional hazard model. We dichotomized log10 SERPINA3 levels based on the value given by HR > 1.

Prognostic value of this cut-off was further evaluated in predicting all-cause mortality, its composite with unplanned cardiac readmission and unplanned cardiac readmission alone in competing risk with mortality. Cumulative survival curves were derived according to the Kaplan–Meier method, and differences between curves were analysed by log-rank test. The Cox proportional hazard model was used to examine predictive role of SERPINA3 for outcomes. Model assumptions for proportionality of hazard were checked based on the cumulative residual approach.12 The observed and simulated score processes were plotted assuming the underlying model has proportional hazard. The Kolmogorov–Smirnov test was used to test the proportional hazard.

Finally, the incremental prognostic value of SERPINA3 was evaluated in the multivariate baseline clinical model including clinical, laboratory or structural, and haemodynamic parameters. They included age, gender, ischaemic aetiology of heart failure, presence of diabetes, eGFR, haemoglobin, white blood cell count > 10 000, CRP, LV end-diastolic diameter and ejection fraction at echocardiography, invasive mean pulmonary artery pressure, mean pulmonary capillary wedge pressure (PCW) pressure together with NT-proBNP > 1000 pg/mL and ST2 > 35 ng/mL levels. The incremental value was assessed by the net reclassification improvement (NRI) index, together with NRI’s for ‘events’ and ‘non-events’. The integrated discrimination improvement and the change under the receiver operating characteristic curve were evaluated. The nested models were compared based on likelihood ratio test. Concordance and Akaike information criteria measures were calculated.13 All statistical tests were considered significant at the P < 0.05 level, except in the selection of possible univariate predictors to enter a multivariate model (P < 0.1).

Results

SERPINA3 in the exploratory cohort of CCMP survivors and non-survivors

Clinical and haemodynamic characteristics of the discovery patient cohort are shown in Table S1. Haemodynamic indices across the groups were consistent with the study design. Among 83 transcripts related to heart failure (Table S2), 14 were up-regulated in surviving and non-surviving patients compared with controls (Table S3). Only SERPINA3 (Figure 1A), ST2 and GDF-15 were up-regulated in non-survivors vs. survivors. Similar to myocardial expression analyses, plasma SERPINA3 levels were significantly higher in CCMP non-survivors vs. survivors or controls (334.7 ± 138.7 vs. 228.2 ± 83.1 and 175.9 ± 27.8 μg/mL respectively, Figure 1B). Myocardial SERPINA3 gene expression
showed significant correlation with serum levels ($r = 0.28$, $P = 0.006$). Its gene expression could not be detected in peripheral blood cells (data not shown).

To address whether increased plasma SERPINA3 levels are related to myocardial production, we determined SERPINA3 myocardial gradients from a difference between the coronary sinus and arterial blood concentration in 25 non-survivors and 25 survivors. Arterial and coronary sinus levels of SERPINA3 were similar (313.3 ± 118.8 and 323.3 ± 122.6 μg/mL, $P = NS$) arguing against significant myocardial gradient (Figure 1C).

We examined whether endothelial cells are responsive to inflammatory stimulation and able to secret SERPINA3. Stimulation of endothelial cell subtypes including human coronary artery endothelial cells (Figure 1D), human umbilical vein cells or blood outgrowth endothelial cells (Figure S1A) by interleukin-1β or tumour necrosis factor-α led to a significant SERPINA3 release. This secretory response was associated with both SERPINA3 gene and protein expression in the cells (Figure S1B). SERPINA3 could be blocked by Brefeldin A indicating its secretion through the ER/Golgi secretory pathway (Figure S1C).
SERPINA3 levels in the validation heart failure cohort

Clinical relevance of elevated SERPINA3 levels was validated in an independent cohort of 387 patients admitted due to de novo or worsened heart failure. In this validation cohort, 80 patients died up to 12 year follow-up. Characteristics of the study population are in Table 1. There were no significant differences in their risk factors, prevalence of female gender, or medications except higher use of diuretics in non-survivors. Both survivors and non-survivors had similar LV volumes and LV function with similar prevalence of heart failure with preserved ejection fraction. Right-sided and left-sided filling pressures were higher in

| Demography and risk factors | Total (N = 387) | Survivors (N = 307) | Non-survivors (N = 80) |
|-----------------------------|----------------|---------------------|------------------------|
| Age (years) at sampling     | 59.56 ± 16.01 | 56.93 ± 15.95       | 69.64 ± 11.75****      |
| Male/female (%)             | 69/31          | 68/32               | 70/30                  |
| BMI (kg/m²)                 | 26.2 ± 4.5     | 26.2 ± 4.5          | 26.0 ± 4.3             |
| Hyperlipidaemia             | 233/387 (60.2%)| 179/307 (58.3%)     | 54/80 (67.5%)          |
| AHT                         | 214/387 (55.3%)| 173/307 (56.4%)     | 41/80 (51.3%)          |
| CAD                         | 101/387 (26.1%)| 68/307 (22.2%)      | 33/80 (41.3%)          |
| Diabetes mellitus           | 88/387 (22.7%) | 62/307 (20.2%)      | 26/80 (32.5%)          |

| Echocardiography            | Total (N = 387) | Survivors (N = 307) | Non-survivors (N = 80) |
|-----------------------------|----------------|---------------------|------------------------|
| LVEDD (mm)                  | 58.2 ± 11.3    | 58.4 ± 11.2          | 57.8 ± 11.7            |
| LVESD (mm)                  | 47.1 ± 12.9    | 47.5 ± 12.9          | 45.7 ± 13.0            |
| LVEF (%)                    | 39.9 ± 18.0    | 40.2 ± 17.9          | 38.8 ± 18.2            |
| HFpEF (%)                   | 40.6%          | 38.8%                | 46.2%                  |
| LVEDP (mmHg)                | 17.3 ± 7.8     | 16.9 ± 7.8           | 18.8 ± 7.5             |
| LVESP (mmHg)                | 117.3 ± 24.2   | 117.2 ± 24.2         | 117.7 ± 24.4           |
| LVDevP (mmHg)               | 100.1 ± 24.3   | 100.4 ± 24.2         | 98.7 ± 24.6            |
| LVESVI (mL/m²)              | 108.2 ± 42.9   | 107.4 ± 42.2         | 111.4 ± 46.1           |
| LV mass index (g/m³)        | 68.0 ± 41.4    | 67.0 ± 40.5          | 72.6 ± 45.0            |
| AP mean (mmHg)              | 13.7 ± 1.9     | 23.4 ± 9.8           | 26.7 ± 9.2**           |
| RV syst (mmHg)              | 47.1 ± 12.9    | 37.1 ± 12.0          | 42.5 ± 13.0**          |
| RV diast (mmHg)             | 8.4 ± 5.1      | 8.0 ± 4.8            | 9.8 ± 6.0*             |
| Mean PCWP (mmHg)            | 15.3 ± 8.1     | 14.5 ± 8.0           | 18.0 ± 7.9***          |
| TAPSE (mm)                  | 18.0 ± 5.0     | 18.0 ± 5.0           | 18.1 ± 5.0             |

| Laboratory parameters       | Total (N = 387) | Survivors (N = 307) | Non-survivors (N = 80) |
|-----------------------------|----------------|---------------------|------------------------|
| WBC (n/µL)                  | 7986 ± 2435   | 7938 ± 2295         | 8166 ± 2918            |
| Haemoglobin (g/dL)          | 13.7 ± 1.9    | 23.9 ± 1.9          | 26.8 ± 2.0***          |
| eGFR (mL/min)               | 66.9 ± 19.3   | 70.6 ± 16.6         | 53.8 ± 22.3****        |
| SGPT (ALT) (U/L)            | 40.1 ± 52.5   | 39.6 ± 47.1         | 42.0 ± 69.3            |
| SGOT (AST) (U/L)            | 34.6 ± 46.3   | 33.3 ± 44.5         | 39.2 ± 52.7            |
| Fe (µg/dL)                  | 81.3 ± 42.1   | 84.1 ± 42.1         | 74.2 ± 39.2            |
| sFerritin (µg/L)            | 286.4 ± 322.9 | 285.9 ± 344.0       | 288.3 ± 225.5          |
| sCHOL (mg/dL)               | 169.4 ± 43.9  | 173.5 ± 43.4        | 153.8 ± 42.7**         |
| ST2 (ng/mL)                 | 42.1 ± 38.1   | 39.0 ± 34.9         | 54.2 ± 46.9**          |
| CRP (mg/L)                  | 16.1 ± 40.3   | 15.8 ± 43.3         | 17.1 ± 25.7**          |
| NT-proBNP (ng/L)            | 4018 ± 5946   | 3205 ± 4920         | 7181 ± 8187****        |
| hsTnT (ng/L)                | 92.1 ± 186.6  | 91.6 ± 199.1        | 94.8 ± 96.8****        |
| SERPINA3 (µg/mL)            | 378.8 ± 186.8 | 364.0 ± 185.8       | 421.0 ± 184.6**        |

| Medication                  | Total (N = 387) | Survivors (N = 307) | Non-survivors (N = 80) |
|-----------------------------|----------------|---------------------|------------------------|
| Beta-blockers               | 266/387 (68.7%)| 214/307 (69.7%)     | 52/80 (65.0%)           |
| ACE/ARB                     | 249/387 (64.3%)| 199/307 (64.8%)     | 50/80 (62.5%)           |
| Mineralkorikoid blocker     | 263/387 (68.0%)| 203/307 (66.1%)     | 60/80 (75.0%)           |
| Diuretics                   | 216/387 (55.8%)| 159/307 (51.8%)     | 57/80 (71.2%)           |

Table 1 Baseline characteristics of patients in the validation cohort of all comers with HF

AHT, arterial hypertension; AP, pulmonary artery pressure; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; Fe, iron; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; hsTnT, high sensitivity troponin T; LVDevP, left ventricular developed pressure; LVEDD, left ventricular end-diastolic diameter; LVESP, left ventricular end-diastolic pressure; LVESVI, left ventricular end-systolic volume index; LVEDVI, left ventricular end-systolic volume; LVEDV, left ventricular end-systolic volume index; LV Mass Index, left ventricular mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCWP, pulmonary capillary wedge pressure; RV diast, right ventricle diastolic pressure; RV syst, right ventricle systolic pressure; sCHOL, serum cholesterol; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; ST2, suppression of tumorigenicity; TAPSE, tricuspid annular plane systolic excursion; WBC, white blood cell count.

\* P < 0.05, \** P < 0.01, \*** P < 0.001, **** P < 0.0001 vs. survivors.
non-survivors vs. survivors. Plasma levels of ST2, NT-proBNP, and CRP were also significantly higher in non-survivors vs. survivors. Serum liver enzymes and ferritin levels were comparable between both groups. Cholesterol levels were lower in non-survivors.

We sought to examine whether laboratory, echocardiographic, and haemodynamic parameters could predict SERPINA3 plasma levels. By using linear regression analysis, none of the echocardiographic or invasive haemodynamic parameters were related to circulating SERPINA3 levels. In contrast, white blood cell counts, haemoglobin, CRP, NT-proBNP, and ST2 plasma levels emerged as univariate predictors of the log10 transformed SERPINA3 blood levels. All these predictors, except white blood cell counts, remained independent predictors in the multivariate model. Yet this multivariate model yielded only limited prediction precision (adjusted $R^2$ multivariate model: 0.279) and could not sufficiently account for extent of the circulating SERPINA3 levels.

**SERPINA3 and clinical outcomes**

Median level of SERPINA3 in the validation cohort was 323 μg/mL (range 116.2–1389.8 μg/mL). In the spline curve analysis, log10 SERPINA3 level of 2.5 corresponding to plasma levels of 316 μg/mL emerged as optimal cut-off value for mortality (Figure IE).

As shown in Figure 2A, patients with SERPINA3 levels > 316 μg/mL had a significantly worse survival (HR [95% confidence interval (CI)]: 2.4 [1.5–3.9], $P = 0.0002$). As the median follow-up in the validation cohort was 41 months and number of patients at risk declined under 100 in each group beyond this time point, further analyses describe the relationship between SERPINA3 levels and clinical outcomes by 3 year follow-up. Survival in patients with SERPINA3 levels > 316 μg/mL was significantly worse as compared with those with levels ≤ 316 μg/mL (Figure 2B: HR [95% CI]: 2.3 [1.1–4.8], $P = 0.024$). While freedom from unplanned cardiac readmissions tended to be worse in patients with high...
SERPINA3 levels [Figure 2C: HR (95% CI): 1.7 (0.9–3.1), \(P = 0.078\)], the freedom from composite of all-cause mortality and unplanned cardiac readmissions was significantly lower compared with patients with lower levels [Figure 2D: HR (95% CI): 2 (1.2–3.3), \(P = 0.004\)].

In further analyses, we explored the added value of SERPINA3 levels to established biomarkers, ST2 and NT-proBNP on mortality and its composite with unplanned cardiac readmission. The survival rate of patients with elevated SERPINA3 > 316 \(\mu\)g/mL and elevated NT-proBNP > 1000 pg/mL was lower as compared with other combinations of both biomarkers (Figure 3A, log-rank test: \(P = 0.037\)). The composite of all-cause mortality and first unplanned cardiac readmission was also worse in patients with elevated levels of both markers as compared with other combinations (Figure 3B). Freedom from this composite endpoint declined to 71% at 1 year follow-up in these patients compared with 84% in patients with low SERPINA3 levels \(\leq 316 \mu\)g/mL and elevated NT-proBNP levels > 1000 pg/mL (risk ratio = 1.87; \(P = 0.058\)).

Elevated SERPINA3 with elevated ST2 > 35 ng/mL was also associated with worse survival (Figure 3C, log-rank test \(P = 0.0081\)) as well as its composite with first unplanned cardiac readmission (Figure 3D, log-rank test \(P = 0.00078\)) as compared with other combinations of both biomarkers. Freedom from both clinical outcomes declined rapidly to 63.6% at 1 year follow-up in patients with high SERPINA3 and ST2 levels compared with 85.2% in patients with elevated ST2 and low SERPINA3 levels (risk ratio: 1.57; \(P = 0.059\)).

A subcohort of patients with elevated SERPINA3 as well as both NT-proBNP and ST2 showed worse survival (Figure S2A) and lower freedom from composite of all-cause mortality and unplanned cardiac readmission at 1 year follow-up (Figure S2B) as compared with other combination of all biomarkers.

**Prognostic value of SERPINA3 in addition to established risk factors and biomarkers**

Cox proportional hazard models were calculated to evaluate the predictive value of the SERPINA3 plasma levels in addition to other clinical parameters for all-cause mortality, its composite with unplanned cardiac readmission, and...
unplanned cardiac readmission alone with mortality as competing risk. Of the 387 patients, 81 were deleted due to missing covariates. Analyses were performed using the remaining 306 observations.

Table 2 shows univariate and multivariate predictors of all-cause mortality by this model. Elevated SERPINA3 emerged as independent predictor of mortality in addition to elevated ST2, eGFR, and mean PCW pressure in a multivariate analysis.

When comparing the final multivariate model with SERPINA3 (c.statistic: 0.77; AIC: 685) and without SERPINA3 (c.statistic: 0.76; AIC: 688), adding increased SERPINA3 to the risk set significantly improved the model fit (likelihood ratio test: \( P < 0.05 \)) indicating its incremental value in predicting the mortality hazard. Adding SERPINA3 plasma levels to the model in predicting the 3 year mortality resulted in continuous NRI (\( >0 \)) of 0.45 (CI: 0.07-0.77, \( P < 0.05 \)). The incremental value of NRI (\( >0 \)) for ‘events’ was 45.2% and NRI (\( >0 \)) for ‘non-events’ was 0.1%. The calculated integrated discrimination improvement was 1.9%, and the increase in area under the curve was 0.5%.

In the analysis of predictors of the composite of mortality with unplanned cardiac readmission, SERPINA3 was a significant univariate predictor but was not retained as independent predictor in the multivariate analysis. Here, elevated NT-proBNP together with ST2, age, eGFR, and PCWP remained independent predictors (c.statistic 0.66). Unplanned cardiac readmission with mortality as competing risk showed only eGFR and ischaemic aetiology as independent predictors (c.statistic: 0.60).

Discussion

In the present study, insights into the potential prognostic role of SERPINA3 in heart failure were enabled by selecting a well-defined, phenotypically matched cohort of survivors and non-survivors with heart failure due to congestive cardiomyopathy. While noting up-regulated myocardial gene expression in non-survivors, circulating levels were not related to myocardial production or cardiac load. In vitro studies suggested ability of endothelial cell subtypes to secretion SERPINA3 in response to inflammatory cytokines. In further validation in an independent cohort of patients with a de novo or worsened heart failure regardless the aetiology and phenotype, circulating SERPINA3 levels were also higher in non-survivors and predictive of poor survival or unplanned cardiac readmission. In particular, elevated SERPINA3 levels in combination with elevated ST2 and NT-proBNP levels appeared to identify a vulnerable population of patients at excessive risk for mortality or unplanned cardiac readmission.

Serpins are a large family of protease inhibitors involved in many biological processes. They are divided into clades based on their phylogenetic relationship, termed A to P. Serpins inhibit serine proteinases by an irreversible suicide substrate mechanism using a unique and extensive conformational change. SERPINA3, also known as alpha-1 antichymotrypsin, is one of the clade A serpins, present with high expression in the retina, kidney, liver, and pancreas. SERPINA3 acts as an inhibitor of several serine proteases, mainly targeting cathepsin G released during the inflammatory response and involved in tissue damage.
SERPINA3 is implicated in the pathology of complex human disorders such as Alzheimer disease with vascular dementia or prion disease. In particular, SERPINA3 overexpression has been documented in several cancer types as a marker of poor prognosis. In experimental heart failure, SERPINA3 appeared to accelerate tumour cells growth and thus was implicated to a cancer development in the clinical heart failure setting. In clinical setting, plasma SERPINA3 levels appear to track favourable remodelling under mechanical haemodynamic support in end-stage heart failure. Increased plasma SERPINA3 concentrations appeared also predictive of adverse outcome in patients with acute myocardial infarction or associated with calcific aortic stenosis.

Our study expands these observations by providing the first direct evidence associating SERPINA3 levels with poor clinical outcome in heart failure. In two distinct cohorts of patients, SERPINA3 levels were consistently higher in non-surviving patients with CCMP or all comers with a de novo or worsened heart failure regardless its phenotype. Our study established a cut-off value of 316 μg/mL predictive of adverse clinical outcome. Patients with SERPINA3 > 316 μg/mL alone or on top of elevated NT-proBNP or ST2 showed increased mortality or its composite with first unplanned cardiac readmission. In addition, elevated SERPINA3 provided additional precision into the prognostic mortality stratification in a model incorporating clinical, laboratory, or haemodynamic risk factors in combination with both biomarkers. Hence, by providing additional prognostic information to either of the established biomarkers, elevated SERPINA3 may help to identify a particularly vulnerable subset of heart failure patients at risk for poor outcomes.

The source of increased circulating plasma SERPINA3 has been primarily attributed to liver. In current heart failure patient cohort, SERPINA3 protein concentrations were similar in coronary sinus and arterial blood despite up-regulated myocardial transcript levels arguing against myocardial secretion. Yet several members of the Serpin family have a half-life of several days, which may cloud the interpretation of transmyocardial gradients with difficulties to discern from measured and biologically relevant gradient that might have been induced rapidly in response to inflammatory cytokines. Our findings provide a new experimental evidence that endothelial cells are able to secret SERPINA3 in response to inflammatory cytokines. The underlying molecular mechanisms appear to be related to direct gene and protein SERPINA3 induction followed by secretion via the ER/Golgi secretory pathway. These findings support the hypothesis that vascular endothelium susceptible to inflammatory stimuli may contribute to elevated circulating SERPINA3 levels in heart failure. Nevertheless, in the multivariate model, circulating inflammatory and humoral factors could not fully account for elevated levels and neither of the echocardiographic nor invasive haemodynamic parameters were associated with increased levels. Further precision in defining the mechanism of elevated SERPINA3 in heart failure is to be determined.

Following limitations should be acknowledged. SERPINA3 has been identified as a potential biomarker within pre-selected gene transcripts. Unbiased genomic or proteomic analyses at myocardial or serum level might have identified other biomarkers of interest. Association between SERPINA3 and clinical outcomes was studied in patients with de novo or worsened heart failure in the limited sample size. Further prospective studies are needed to validate its prognostic value either alone or in the multimarker strategy in addition to NT-proBNP and ST2 in larger heart failure population. Likewise, male gender was predominant in our population. Although gender did not emerge as independent risk factor, gender differences in SERPINA3 levels in relation to clinical outcomes require further investigation. It is also noteworthy that clinical factors such as renal failure or ischaemic aetiology remained strong predictors of unplanned cardiovascular readmissions alone or in combination with mortality emphasizing their relevance in risk models addressing the prognostic value of circulating biomarkers. Circulating SERPINA3 has been determined at one point time during the admission. The relevance of its dynamic changes in the later stages for prognostic stratification after reaching euvoletic state after discharge remains unknown. The clinical relevance of individual variations in the SERPINA levels within survivors cohort also requires further investigation. Our study attempted primarily to decipher the mechanisms of SERPINA production and its prognostic value. Its potential effects on endothelial cell function or cardiac myocytes as contributing to heart failure pathophysiology are of interest and require further studies.

In conclusion, we identified SERPINA3 as a potential prognostic biomarker in heart failure. Elevated SERPINA3 > 316 μg/mL appears to be associated with higher mortality or its composite with unplanned cardiac readmission. SERPINA3 appears to provide also additional prognostic information in risk models incorporating demographic, clinical, haemodynamic, and laboratory risk including ST2 and NT-proBNP by identifying a vulnerable subgroup of heart failure patients at increased mortality risk. These findings warrant further validation in prospectively designed studies including a broad population of heart failure patients.

Conflict of interest

There are no conflicts of interest related to this study.

Funding

This study has been supported by VZW Cardiovascular Research Centre Aalst, Belgium.
Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Baseline characteristics of patients in the exploratory cohort of matched survivors and non-survivors with HF due to idiopathic cardiomyopathy.

Table S2. A total of 83 transcripts involved in heart failure were analysed in surviving and non-surviving heart failure patients.

Table S3. Differentially myocardial expressed genes (n = 14) in CCMP survivors and non-survivors vs control patients.

(*p < 0.05; **p < 0.01; ***p < 0.001 vs Controls).

References

1. Kumani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep 2017; 14: 385–392.
2. Gaggin HK, Januzzi JL. Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013; 1832: 2442–2450.
3. Wettersten N, Maisel AS. Biomarkers for heart failure: an update for practitioners of internal medicine. Am J Med 2016; 129: 560–567.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Niitsoyanopoulos P, Parissis JT, Pieke B, Riley JP, Rosano GMC, Ruijgrok LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
5. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 2017; 135: e1054–e1091.
6. Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinical care. Card Fail Rev 2019; 5: 50–56.
7. Demissei BG, Postmus D, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Dittrich HC, Hilleges HL, Voors AA. Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. Eur J Heart Fail 2017; 19: 728–738.
8. Baker C, Belbin O, Kalsheker N, Morgan D, Naish J, O'Donnell R, Parrella AT, Russell J, Smith P, Waldron N, Wrigley T. SERPINA3 (aka alpha-1-antichymotrypsin). Front Biosci 2007; 12: 2821–2835.
9. Lok SJ, van Mil A, Bovenschen N, van der Weide P, van Kuijk J, van Wichen D, Weerts T, Siera E, Winkens B, Sluijter J, Doevendans PA, da Costa Martins PA, de Jonge N, de Weger RA. Post-transcriptional regulation of alpha-1-antichymotrypsin by microRNA-137 in chronic heart failure and mechanical support. Circ Heart Fail 2013; 6: 853–861.
10. Bernstein LH, Zions MY, Tetrault WJ, Westlake MM, Heistad DD, van de Weide F. Role of circulating precursor blood outgrowth endothelial cells (BOEC) after IL-1β and TNF-α stimulation compared to unstimulated cells. Panel B: IL-1β stimulation of HCAEC induces SERPINA3 secretion and an increase in both SERPINA3 transcripts and protein. Panel C: Brefeldin A, a blocker of protein secretion through the ER/Golgi, is able to block SERPINA3 secretion.

Figure S1. Panel A: Fold increase in SERPINA3 protein secretion in human umbilical vein endothelial cells (HUVEC) and circulating precursor blood outgrowth endothelial cells (BOEC) after IL-1β and TNF-α stimulation compared to unstimulated cells. Panel B: IL-1β stimulation of HCAEC induces SERPINA3 secretion and an increase in both SERPINA3 transcripts and protein. Panel C: Brefeldin A, a blocker of protein secretion through the ER/Golgi, is able to block SERPINA3 secretion.

Figure S2. Relationship between SERPINA3 levels and clinical outcome in combination with both NT-proBNP and ST2. Panel A shows Kaplan-Meier curves of all-cause mortality till one year. Panel B shows composite endpoint of survival and first unplanned cardiac readmission.

Table S1: Panel A: Fold increase in SERPINA3 protein secretion in human umbilical vein endothelial cells (HUVEC) and circulating precursor blood outgrowth endothelial cells (BOEC) after IL-1β and TNF-α stimulation compared to unstimulated cells. Panel B: IL-1β stimulation of HCAEC induces SERPINA3 secretion and an increase in both SERPINA3 transcripts and protein. Panel C: Brefeldin A, a blocker of protein secretion through the ER/Golgi, is able to block SERPINA3 secretion.
22. Zhou J, Cheng Y, Tang L, Martinka M, Kalia S. Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells. *Oncotarget* 2017; 8: 18712–18725.

23. Luo D, Chen W, Tian Y, Li J, Xu X, Chen C, Li F. Serpin peptidase inhibitor, clade a member 3 (SERPINA3) is overexpressed in glioma and associated with poor prognosis in glioma patients. *Onco Targets Ther* 2017; 10: 2173–2181.

24. Yang GD, Yang XM, Lu H, Ren Y, Ma M, Zhu L, Wang J, Song W, Zhan R, Zhang Z. SERPINA3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis. *Int J Clin Exp Pathol* 2014; 7: 1348–1358.

25. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA. Heart failure stimulates tumor growth by circulating factors. *Circulation* 2018; 138: 678–691.

26. Zhao L, Zheng M, Guo Z, Li K, Liu Y, Chen M, Yang X. Circulating SERPINA3 levels predict the major adverse cardiac events in patients with myocardial infarction. *Int J Cardiol* 2020; 300: 34–38.

27. Martin-Rojas T, Mourino-Alvarez L, Gil-Dones F, de la Cuesta F, Rosello-Lleti E, Laborde CM, Rivera M, Lopez-Almodovar LF, Lopez JA, Akerstrom F, Padial LR, Bareras MG. A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis. *Clin Proteom* 2017; 14: 12–22.

28. Travis J, Salvesen GS. Human plasma proteinase inhibitors. *Annu Rev Biochem* 1983; 52: 655–709.

29. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. *J Thromb Haemost* 2007; 5: 102–115.